Starpharma Holdings Ltd (SPL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Starpharma Holdings Ltd (SPL) has a cash flow conversion efficiency ratio of -0.517x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-7.12 Million ≈ $-5.04 Million USD) by net assets (AU$13.78 Million ≈ $9.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SPL stock market capitalisation for the company's overall valuation and market capitalisation.
Starpharma Holdings Ltd - Cash Flow Conversion Efficiency Trend (2001–2026)
This chart illustrates how Starpharma Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Starpharma Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Starpharma Holdings Ltd ranked by their cash flow conversion efficiency. Explore Starpharma Holdings Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Boryszew SA
WAR:BRS
|
0.012x |
|
Xperi Corp
NYSE:XPER
|
0.237x |
|
Aurion Resources Ltd
V:AU
|
-0.009x |
|
Leonteq AG
SW:LEON
|
0.774x |
|
Zhangjiagang Haiguo New Energy Equipment Manufacturing Co. Ltd.
SHE:301063
|
N/A |
|
COG Financial Services Ltd
AU:COG
|
0.198x |
|
TSC Auto ID Technology Co Ltd
TWO:3611
|
0.005x |
|
i3 Verticals Inc
NASDAQ:IIIV
|
0.036x |
Annual Cash Flow Conversion Efficiency for Starpharma Holdings Ltd (2001–2026)
The table below shows the annual cash flow conversion efficiency of Starpharma Holdings Ltd from 2001 to 2026. View today's stock price for Starpharma Holdings Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | AU$13.78 Million ≈ $9.75 Million |
AU$-3.21 Million ≈ $-2.27 Million |
-0.233x | +34.51% |
| 2025-06-30 | AU$19.00 Million ≈ $13.44 Million |
AU$-6.76 Million ≈ $-4.78 Million |
-0.356x | -43.37% |
| 2024-06-30 | AU$28.12 Million ≈ $19.89 Million |
AU$-6.98 Million ≈ $-4.94 Million |
-0.248x | +36.16% |
| 2023-06-30 | AU$34.81 Million ≈ $24.63 Million |
AU$-13.53 Million ≈ $-9.58 Million |
-0.389x | -42.92% |
| 2022-06-30 | AU$48.39 Million ≈ $34.24 Million |
AU$-13.16 Million ≈ $-9.31 Million |
-0.272x | -14.43% |
| 2021-06-30 | AU$62.30 Million ≈ $44.08 Million |
AU$-14.81 Million ≈ $-10.48 Million |
-0.238x | +30.90% |
| 2020-06-30 | AU$31.33 Million ≈ $22.17 Million |
AU$-10.78 Million ≈ $-7.62 Million |
-0.344x | -40.99% |
| 2019-06-30 | AU$42.40 Million ≈ $30.00 Million |
AU$-10.34 Million ≈ $-7.32 Million |
-0.244x | -27.43% |
| 2018-06-30 | AU$53.28 Million ≈ $37.70 Million |
AU$-10.20 Million ≈ $-7.22 Million |
-0.191x | +31.13% |
| 2017-06-30 | AU$60.98 Million ≈ $43.15 Million |
AU$-16.95 Million ≈ $-12.00 Million |
-0.278x | +22.85% |
| 2016-06-30 | AU$49.42 Million ≈ $34.97 Million |
AU$-17.81 Million ≈ $-12.60 Million |
-0.360x | +0.59% |
| 2015-06-30 | AU$37.56 Million ≈ $26.57 Million |
AU$-13.62 Million ≈ $-9.63 Million |
-0.363x | -21.73% |
| 2014-06-30 | AU$32.95 Million ≈ $23.31 Million |
AU$-9.81 Million ≈ $-6.94 Million |
-0.298x | -39.76% |
| 2013-06-30 | AU$45.97 Million ≈ $32.53 Million |
AU$-9.79 Million ≈ $-6.93 Million |
-0.213x | -6.11% |
| 2012-06-30 | AU$48.65 Million ≈ $34.42 Million |
AU$-9.77 Million ≈ $-6.91 Million |
-0.201x | +14.13% |
| 2011-06-30 | AU$27.69 Million ≈ $19.59 Million |
AU$-6.48 Million ≈ $-4.58 Million |
-0.234x | -124.47% |
| 2010-06-30 | AU$34.84 Million ≈ $24.65 Million |
AU$-3.63 Million ≈ $-2.57 Million |
-0.104x | +34.07% |
| 2009-06-30 | AU$25.50 Million ≈ $18.04 Million |
AU$-4.03 Million ≈ $-2.85 Million |
-0.158x | +39.82% |
| 2008-06-30 | AU$20.38 Million ≈ $14.42 Million |
AU$-5.35 Million ≈ $-3.79 Million |
-0.263x | -99.82% |
| 2007-06-30 | AU$25.72 Million ≈ $18.20 Million |
AU$-3.38 Million ≈ $-2.39 Million |
-0.131x | +62.60% |
| 2006-06-30 | AU$21.32 Million ≈ $15.08 Million |
AU$-7.49 Million ≈ $-5.30 Million |
-0.351x | +39.71% |
| 2005-06-30 | AU$9.97 Million ≈ $7.05 Million |
AU$-5.81 Million ≈ $-4.11 Million |
-0.583x | -76.57% |
| 2004-06-30 | AU$17.59 Million ≈ $12.45 Million |
AU$-5.81 Million ≈ $-4.11 Million |
-0.330x | +22.04% |
| 2002-06-30 | AU$17.27 Million ≈ $12.22 Million |
AU$-7.31 Million ≈ $-5.17 Million |
-0.423x | -329.93% |
| 2001-06-30 | AU$24.92 Million ≈ $17.63 Million |
AU$-2.45 Million ≈ $-1.74 Million |
-0.098x | -- |
About Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRA… Read more